Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
Conditions
Interventions
Lurbinectedin
Doxorubicin
Locations
6
United States
Mayo Arizona
Phoenix, Arizona, United States
Mayo Jacksonville
Jacksonville, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Rochester
Rochester, Minnesota, United States
Memorial Sloan Kettering
New York, New York, United States
Start Date
February 4, 2022
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2027
Last Updated
April 13, 2026
NCT05182164
NCT07405346
NCT05836571
NCT05100628
NCT05043649
NCT05174455
Lead Sponsor
Massachusetts General Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions